Previous 10 | Next 10 |
home / stock / ipatf / ipatf news
ImmunoPrecise Antibodies ( OTCQB:IPATF -3.4% ) subsidiary U-Protein Express BV announces the availability of new recombinant SARS-CoV-2 proteins, along with other COVID-19-associated proteins, for research use in the design and discovery of diagnostic tests, therapeutics and vaccines for...
Recombinant SARS-CoV-2 Proteins Now Available For Research From ImmunoPrecise's European Subsidiary, UPE Canada NewsWire UTRECHT, Netherlands, June 11, 2020 UTRECHT, Netherlands , June 11, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: I...
VICTORIA, BC , June 4, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced it is collaborating, pursuant to an agreement...
NSERC Awards Grant to Fund Collaboration Between ImmunoPrecise and the University of Victoria for the Generation of a Potential COVID-19 Antibody-Based Test in Canada that can Provide Real-Time Responses Canada NewsWire VICTORIA, May 27, 2020 VICTORIA , May 27, 2020 /CNW/...
ImmunoPrecise Closes Oversubscribed Debenture Financing Canada NewsWire VICTORIA, May 15, 2020 VICTORIA , May 15, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to announce that it has closed its previousl...
ImmunoPrecise Increases Financing to $2.592 Million Canada NewsWire VICTORIA, May 15, 2020 VICTORIA , May 15, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to announce that it has increased its previously...
ImmunoPrecise Increases Financing to $2.3 Million and Makes Payment in Respect of Deferred Purchase Price for IPA Europe and Immulease Canada NewsWire VICTORIA, May 8, 2020 VICTORIA , May 8, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE:...
ImmunoPrecise Antibodies Increases Discovery Capabilities to Help Pinpoint Lead Drug Candidates with Addition of Octet HTX Canada NewsWire VICTORIA, May 6, 2020 VICTORIA , May 6, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (...
ImmunoPrecise Updates on State and Federal Funding Canada NewsWire FARGO, ND, April 24, 2020 IPA Awarded Grant Focused on Coronavirus and Other Emerging Pathogens FARGO, ND , April 24, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTU...
Janssen Signs Collaboration with ImmunoPrecise Antibodies Johnson & Johnson ( JNJ ) reported that its biotech unit Janssen Research & Development has signed a new deal with ImmunoPrecise Antibodies Ltd. ( IPATF ). The new deal offers Janssen an exclusive access to an array of novel...
News, Short Squeeze, Breakout and More Instantly...
ImmunoPrecise Antibodies Ltd. Company Name:
IPATF Stock Symbol:
OTCMKTS Market:
ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange Canada NewsWire VICTORIA, BC , Dec. 23, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (Nasdaq Global Markets: IPA), a leader in full-service, therapeu...
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year Canada NewsWire Record Quarterly Revenue of $4,754,545 and Adjusted EBITDA of $795,159 Announced Strategic Partnership ...
ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate VICTORIA, BC , Dec. 14, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. ("IPA") (TSXV: IPA) (IPATD: IPA) (FSE: TQB), a leader in full-service, therapeutic antibody discovery and development and LiteVax...